Inactive Instrument

GlaxoSmithKline plc Stock London S.E.

Equities

Pharmaceuticals

End-of-day quote London S.E.
- GBX - Intraday chart for GlaxoSmithKline plc
Sales 2024 * 31.58B 39.64B Sales 2025 * 33.51B 42.06B Capitalization 70.49B 88.48B
Net income 2024 * 5.59B 7.01B Net income 2025 * 6.47B 8.13B EV / Sales 2024 * 2.62 x
Net Debt 2024 * 12.32B 15.46B Net Debt 2025 * 9.13B 11.46B EV / Sales 2025 * 2.38 x
P/E ratio 2024 *
12.7 x
P/E ratio 2025 *
10.9 x
Employees -
Yield 2024 *
3.53%
Yield 2025 *
3.66%
Free-Float 94.38%
More Fundamentals * Assessed data

Latest transcript on GlaxoSmithKline plc

Managers TitleAgeSince
Chief Executive Officer 55 10-04-30
Director of Finance/CFO 62 23-04-30
Compliance Officer - 95-07-31
Members of the board TitleAgeSince
Director of Finance/CFO 62 23-04-30
Chairman 66 19-08-31
Director/Board Member 65 14-12-31
More insiders
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat different diseases. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes more than 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines include medicines for immune-mediated conditions. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases.
Calendar
More about the company